With a philanthropic investment of $100 million, the new institute will leverage the collective strengths of Boston and HMS-affiliated immunology and biomedical experts and their collaborations with some of the world’s most distinguished scientists. Kuchroo will lead day-to-day operations, convening core and affiliated faculty and trainees around three central platforms: basic science, translational science, and technology. The primary areas of research will include basic understanding of immune-mediated diseases, ageing, and cancer and translation of this knowledge to the development of new immunotherapies. In addition, the Gene Lay Institute will provide substantial training opportunities for students and fellows to support immunology innovators of the future.
“We are honoured to receive this historic and visionary gift from Dr Lay, who is deeply committed to solving an emerging trend in medicine – the rise of chronic inflammation associated with increased levels of disease and suffering,” said Robert S.D. Higgins, MD, MSHA, president of the Brigham and executive vice president of Mass General Brigham. “This will amplify our ability to improve the quality of patients’ lives across the country and around the world. We’re thrilled to be part of this pivotal moment in the field of medicine.”
Kuchroo said: “During the past several decades, the astounding rise in inflammatory diseases has made it increasingly clear that chronic inflammation is a root cause of many diseases – not only allergies and autoimmune diseases, but also cancer and neurodegenerative, cardiovascular, and metabolic diseases. This transformative gift and investment will allow some of the best immunologists of our time to address this epidemic head-on and build new knowledge to promote basic understanding for preventing and treating immune-mediated diseases.”
Lay is the founder of San Diego-based BioLegend, now part of Revvity, which is a global life sciences and diagnostics company. BioLegend focuses on the development and production of high-quality antibodies, proteins, and assays for cellular immunity, inflammation, cancer, stem cells, and other reagents required for research and diagnosis. Since its founding in 2002, BioLegend has expanded its reach across the globe, with research and development facilities in Taiwan and Japan, as well as subsidiaries in Taiwan, Japan, China, Germany, the United Kingdom, the Netherlands, and France. Lay continues to give back to the scientific community while pursuing his dream of cultivating more expertise in Taiwan, the country where he was born.